PARP14 inhibition restores PD-1 immune checkpoint inhibitor response following IFNγ-driven acquired resistance in preclinical cancer models

Resistance mechanisms to immune checkpoint blockade therapy (ICBT) limit its response duration and magnitude. Paradoxically, Interferon γ (IFNγ), a key cytokine for cellular immunity, can promote ICBT resistance. Using syngeneic mouse tumour models, we confirm that chronic IFNγ exposure confers resi...

Descripción completa

Detalles Bibliográficos
Autores principales: Wong, Chun Wai, Evangelou, Christos, Sefton, Kieran N., Leshem, Rotem, Zhang, Wei, Gopalan, Vishaka, Chattrakarn, Sorayut, Fernandez Carro, Macarena Lucia, Uzuner, Erez, Mole, Holly, Wilcock, Daniel J., Smith, Michael P., Sergiou, Kleita, Telfer, Brian A., Isaac, Dervla T., Liu, Chang, Perl, Nicholas R., Marie, Kerrie, Lorigan, Paul, Williams, Kaye J., Rao, Patricia E., Nagaraju, Raghavendar T., Niepel, Mario, Hurlstone, Adam F. L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10522711/
https://www.ncbi.nlm.nih.gov/pubmed/37752135
http://dx.doi.org/10.1038/s41467-023-41737-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10522711/
https://www.ncbi.nlm.nih.gov/pubmed/37752135
http://dx.doi.org/10.1038/s41467-023-41737-1

Ejemplares similares